{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:15:41Z","timestamp":1790072141089,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-075-051-MY3"],"award-info":[{"award-number":["113-2314-B-075-051-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-128"],"award-info":[{"award-number":["V114C-128"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jfma.2025.10.019","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:21:57Z","timestamp":1760674917000},"page":"S55-S64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Neuromyelitis optica spectrum disorder (NMOSD): Recent advances and insights from Taiwan"],"prefix":"10.1016","volume":"125","author":[{"given":"Wen-Yu","family":"Ou Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3002-4260","authenticated-orcid":false,"given":"Kai-Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Cherng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-2086","authenticated-orcid":false,"given":"Yi-Chu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9451","key":"10.1016\/j.jfma.2025.10.019_bib3","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","article-title":"Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease","volume":"3","author":"Fujihara","year":"2012","journal-title":"Clin Experiment Neuroimmunol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.019_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"issue":"4\u20135","key":"10.1016\/j.jfma.2025.10.019_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/13524585231151953","article-title":"A national case-control study investigating demographic and environmental factors associated with NMOSD","volume":"29","author":"Rotstein","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.jfma.2025.10.019_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102425","article-title":"Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015","volume":"45","author":"Fang","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jfma.2025.10.019_bib10","series-title":"Prevalence of neuromyelitis optica spectrum disorder in the United States. Multiple sclerosis (Houndmills, Basingstoke, England)","author":"Briggs","year":"2024"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.019_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jfma.2021.11.002","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","volume":"121","author":"Liu","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.10.019_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105683","article-title":"Impact of comorbidities on relapsing rates of neuromyelitis optica spectrum disorders: insights from a longitudinal study in Taiwan","volume":"87","author":"Hsu","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000322740","article-title":"The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan","volume":"65","author":"Wang","year":"2011","journal-title":"Eur Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.019_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.jfma.2025.10.019_bib16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2025.10.019_bib17","article-title":"Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study","volume":"2","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.jfma.2025.10.019_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Nationwide epidemiological study of neuromyelitis optica in Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.jfma.2025.10.019_bib19","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e115","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder in Korea: population based study","volume":"35","author":"Lee","year":"2020","journal-title":"J Kor Med Sci"},{"issue":"14","key":"10.1016\/j.jfma.2025.10.019_bib20","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sepulveda","year":"2018","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ene.14079","article-title":"A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary","volume":"27","author":"Papp","year":"2020","journal-title":"Eur J Neurol"},{"issue":"24","key":"10.1016\/j.jfma.2025.10.019_bib22","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.019_bib23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen3.12458","article-title":"Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study","volume":"9","author":"Holroyd","year":"2018","journal-title":"Clin Exp Neuroimmunol"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.019_bib25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00415-019-09647-9","article-title":"Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan","volume":"267","author":"Lin","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.msard.2017.10.007","article-title":"Neuromyelitis optica spectrum disorders in Iran","volume":"18","author":"Eskandarieh","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jfma.2025.10.019_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105923","article-title":"Preceding hepatitis B virus infection is highly prevalent in patients with neuromyelitis optica spectrum disorder in Taiwan","volume":"92","author":"Ou Yang","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3988\/jcn.2022.18.2.152","article-title":"An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders","volume":"18","author":"Jeyalatha","year":"2022","journal-title":"J Clin Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.019_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.10.019_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","article-title":"Temporal trends in the incidence of multiple sclerosis: a systematic review","volume":"71","author":"Alonso","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.019_bib33","article-title":"Patterns of adult neuromyelitis optica spectrum disorder patients compared to multiple sclerosis: a systematic review and meta-analysis","volume":"15","author":"Alqwaifly","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.019_bib35","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.019_bib36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.019_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.019_bib39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.019_bib40","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.019_bib41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458511424590","article-title":"Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jfma.2025.10.019_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.635419","article-title":"Anti-aquaporin 4 IgG is not associated with any clinical disease characteristics in neuromyelitis optica spectrum disorder","volume":"12","author":"Schmetzer","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2014.11.004","article-title":"Biomarkers for neuromyelitis optica","volume":"440","author":"Chang","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"13","key":"10.1016\/j.jfma.2025.10.019_bib44","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib45","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer","year":"2014","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001491","article-title":"Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study","volume":"12","author":"Tsai","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jfma.2025.10.019_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2377-10-45","article-title":"Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis","volume":"10","author":"Nakajima","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib50","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.019_bib51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/jnnp-2023-332663","article-title":"Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients","volume":"95","author":"Uzawa","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jfma.2025.10.019_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WNO.0b013e318283c3ed","article-title":"Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system","volume":"33","author":"Storoni","year":"2013","journal-title":"J Neuro Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.019_bib54","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458513495581","article-title":"\"Bright spotty lesions\" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis","volume":"20","author":"Yonezu","year":"2014","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.019_bib57","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ene.14654","article-title":"Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: a comparative study in Chinese Han patients","volume":"28","author":"ZhangBao","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.0b013e3182648bc8","article-title":"Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis","volume":"79","author":"Tea","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.019_bib59","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jfma.2025.10.019_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103786","article-title":"Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus","volume":"62","author":"Zhang","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jfma.2025.10.019_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.859276","article-title":"Relatively early and late-onset neuromyelitis optica spectrum disorder in central China: clinical characteristics and prognostic features","volume":"13","author":"Yu","year":"2022","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.019_bib62","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jfma.2025.10.019_bib63","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: a multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2025.10.019_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jfma.2025.10.019_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"10.1016\/j.jfma.2025.10.019_bib66","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.jfma.2025.10.019_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.019_bib68","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib69","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.019_bib70","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.019_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib72","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.019_bib73","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib74","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jfma.2025.10.019_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.019_bib76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib77","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/CON.0000000000000337","article-title":"Neuromyelitis optica spectrum disorders","volume":"22","author":"I","year":"2016","journal-title":"Continuum"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.019_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.019_bib79","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.019_bib80","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.019_bib81","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-Positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"10206","key":"10.1016\/j.jfma.2025.10.019_bib82","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.019_bib83","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.jfma.2025.10.019_bib84","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:03:30Z","timestamp":1785891810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625005637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":84,"alternative-id":["S0929664625005637"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.019","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica spectrum disorder (NMOSD): Recent advances and insights from Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}